For many, engagement of more patients in drug development means actually including them in drug trials, to the advantage of both research and the physicians and patients who seek treatment options.
In this session, longstanding leaders of the space will present the current environment for Expanded Access to investigational drugs. Panelists will cover best practices of regulated pre-approval access as well as the future, including trial-site collaboration, payer systems and data collection. Additionally, panelists will explore new possible uses of Expanded Access programs, which may include personalized medicine approaches that allow discovery of targetable subpopulations, ready-response to new contagion outbreaks with investigational drugs and collaborative funding models.
Session ID: 21849